At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 23, 2026 at 17:02 ET
Theravance Biopharma disclosed the planned departure of SVP Development and Head of Ireland Office, Dr. ine Miller, effective November 15, 2026, under a compromise agreement tied to the restructuring announced in March 2026. The filing includes a grant of 18,750 RSUs and a $250,000 pension contribution. This is a routine, previously anticipated executive exit with no unexpected C-suite changes.
- Dr. ine Miller, SVP Development and Head of Ireland Office, will terminate employment on November 15, 2026.
- Departure is part of the restructuring announced by the company in March 2026.
- Dr. Miller received a grant of 18,750 restricted share units on June 19, 2026.
- The company will make a special pension contribution of $250,000 within 30 days of the termination date.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access